Aviir Inc., an Irvine, California-based biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, raised $10m as a second tranche of a possible financing of $30m.
The round was led by Merck Global Health Innovation Fund, with participation from Partners & Partners and existing investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners.
Founded in 2005 and led by Douglas Harrington, M.D., Chief Executive Officer, Aviir focuses on discovery, development and commercialization of innovative diagnostic tests.
The company intends to use the capital to launch its proprietary cardiac risk assessment technology, MIRISK VP™, and additional laboratory testing services, nationwide.
FinSMEs
12/02/2013